Aggregation, Scale, and the Value Chain: Decoding Ten Diverse Business ModelsGlobal Report·1 day ago, 04:15 AMIBRX-1.76%VLN-4.60%
Inside the Biotech Sector's Recent Clinical Catalyst WaveGlobal Report·2 days ago, 04:17 AMGENB+2.31%IBRX-1.76%
monday.com's AI Pivot and Tron's Token Buildup Highlight Small-Cap RealignmentsGlobal Report·2 days ago, 04:14 AMMNDY+6.20%MWC-6.37%
The 2026 Biotech Divide: When Generative Biology Meets the FDA WallGlobal Report·Jul 24 at 04:13 AMINM+2.34%TXG-2.57%
Ripping Up the Playbook: The Radical Strategic Pivots Reshaping the MarketGlobal Report·Jul 22 at 04:18 AMCRMD-0.25%BAM+2.03%
Are Surging IBRX Retail Debates Hinting at a Deeper Re‑rating of ImmunityBio’s Platform?Simplywall·Jul 15 at 04:13 AMIBRX-1.76%
Squeeze Watch: 10 Stocks Bears Love to Hate Most Right Nowbenzinga_article·Jul 13 at 01:29 PMSOUN+3.49%FLNC-2.01%
Insider Selling: ImmunityBio (NASDAQ:IBRX) Director Sells $1,246,495.00 in StockMarket Beat·Jul 7 at 07:53 AMIBRX-1.76%
ImmunityBio director Christobel Selecky disposes of 159,478 common shares worth $1.44 millionPUBT·Jul 6 at 07:26 PMIBRX-1.76%
ImmunityBio director Christobel Selecky disposes of 96,722 common shares worth $870,677.29PUBT·Jul 1 at 04:05 PMIBRX-1.76%
ImmunityBio Director Barry J. Simon disposes of 25,000 common shares worth $196,907.50PUBT·Jun 26 at 08:02 PMIBRX-1.76%
Jim Cramer Calls CAVA 'Tasty, Clean, Fun,' Says Make This Biotech 'Your Speculation'benzinga_article·Jun 17 at 06:50 AMCAVA+1.88%IBRX-1.76%
Lightning round: Trulieve is a terrific spec, says Jim CramerMSN·Jun 16 at 06:43 PMCAVA+1.88%IBRX-1.76%
3 Growth Companies With High Insider Ownership Seeing Up To 94% Earnings GrowthSimplywall·Jun 8 at 12:28 PMLIFE+4.11%IBRX-1.76%
